Drug intelligence / Profile preview

AVA6103

Development stage: Phase 1
Lead developer: Avacta
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

AVA6103 is a peptide-drug conjugate (PDC) developed by Avacta Group plc. It utilizes the pre|CISION platform to deliver the potent topoisomerase I inhibitor exatecan directly to the tumor microenvironment. This is achieved through cleavage by fibroblast activation protein (FAP), which is overexpressed in many solid tumors. AVA6103 aims to minimize systemic toxicity while maximizing antitumor activity. It has shown significant tumor growth inhibition and durable complete responses in preclinical models.

Other names: FAP-EXd

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on AVA6103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVA6103.

Explore the full profile